A New Era in Precision Neuroscience

Fred Callori is CEO and a Co-Founder of Neurosterix. He is also a Managing Director at Perceptive Advisors, where he helps lead the firm’s venture strategy.

As Co-Founder and CEO of Neurosterix, Mr. Callori has been instrumental in shaping the company’s strategy, operations, and external relationships, building on his extensive experience in company creation, venture investment, and operational leadership at Perceptive.

Prior to joining Perceptive and co-founding Neurosterix, Mr. Callori was a Partner in the Life Science and Emerging Companies practices at Choate, Hall & Stewart LLP, where he advised investors and entrepreneurs on private equity and venture capital transactions.

He holds a BA in Economics from Binghamton University and a JD from Boston University School of Law.

Robert Lütjens, PhD is the Chief Scientific Officer at Neurosterix, with more than 20 years of experience in CNS drug discovery. He has a proven track record of advancing molecules from early hit identification to clinical candidates, with several programs reaching Phase I and proof-of-concept studies. Prior to Neurosterix, he spent over two decades at Addex Therapeutics, where he established the biology department and built the company’s pioneering allosteric modulator platform. Under his leadership, Addex advanced multiple internal and partnered programs, including dipraglurant and ADX71149 into Phase II development, and he helped forge collaborations with Janssen, Merck, and Indivior. He also contributed to business development and investor relations, supporting the company in securing over CHF 400 million in equity and partnerships, along with CHF 10 million in non-dilutive funding.

Dr. Lütjens conducted postdoctoral research at The Scripps Research Institute in La Jolla, CA, focused on the molecular mechanisms of addiction. He earned his PhD through work at the Glaxo Institute for Molecular Biology in Geneva and the University of Lausanne, following a Master’s at the Swiss Institute for Experimental Cancer Research and Biology studies at the University of Geneva. He is an inventor on multiple patents and co-author of more than 30 peer-reviewed publications, with significant contributions to the field of allosteric drug discovery.

Dr. Feltner, MD is a physician-scientist with more than 25 years of experience in clinical drug development and translational medicine, with a focus on neurology, psychiatry, and neuroscience. He has held senior leadership roles in the pharmaceutical industry, including Vice President, Neuroscience Development at AbbVie and Vice President, Global Head of Translational Medicine at Pfizer, and Chief Medical Officer at AveXis.

Dr. Feltner has led programs across a wide range of neurological and psychiatric indications, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, schizophrenia, depression, anxiety, bipolar disorder, pain, and rare neurodegenerative diseases. His expertise spans biologics, small molecules, gene therapy, and drug-device combinations, with extensive regulatory experience across BLA, MAA, NDA, and JNDA submissions.

He earned his MD with distinction in research from the University of Michigan Medical School, completed his psychiatry residency at George Washington University, and was a postdoctoral fellow in the Laboratory of Mammalian Genes and Development at the National Institute of Child Health and Human Development.

Ted joined Neurosterix in May of 2025 to serve as Chief Operating Officer (COO). He brings over 25 years of industry experience working in both large and small biopharma companies in roles spanning the entire value chain. He joined Neurosterix most recently from Kisbee Therapeutics where he also served as COO. Prior to Kisbee, Ted was an early employee of Cerevel Therapeutics where he ran portfolio and program management and helped grow the company from 10 employees to 150+, launch 14 clinical trials, and complete an IPO. Before Cerevel, Ted spent 7 years at Biogen first in Corporate Strategy and then as Vice President of R&D Business Operations. Before Biogen, Ted held positions of increasing responsibility at Pfizer, Deloitte Consulting, and Exact Sciences. Ted holds an MBA from Babson College and a B.A in Biology from Colby College.

Dr. Dominik Schelshorn is Head of Biology at Neurosterix, where he brings more than 15 years of experience in GPCR research and allosteric modulator pharmacology. At Neurosterix, he leads biology programs – including the M4 program, which he helped advance through development – and drives collaborations with academic and industry partners. His expertise in developing proprietary tools to measure GPCR activity and in understanding allosteric mechanisms has been central to strengthening Neurosterix’s discovery platform and advancing its pipeline.

Prior to joining Neurosterix, Dr. Schelshorn held increasingly senior roles at Addex Therapeutics, where he played a key role in advancing the company’s allosteric modulator programs and discovery capabilities. He earned his Diploma in Molecular and Cellular Biology and his PhD in Neurophysiology from the University of Heidelberg, where he graduated summa cum laude.

Dr. Paparin is a recognized drug hunter with over 20 years of experience in medicinal chemistry, delivering innovative therapies from the exploratory phase to the clinic. With expertise across multiple target classes, he currently leads several neuroscience programs at Neurosterix as Head of Discovery Chemistry, overseeing projects from early discovery through clinical candidate selection and managing world-class cross-functional teams. His work focuses on designing better drugs to address unmet medical needs.

Prior to Neurosterix, Dr. Paparin served as Director of Medicinal Chemistry at Addex Therapeutics, where he successfully led M4 PAM and mGlu7 NAM projects. He also held leadership roles as Drug Development Project Coordinator at Enyo and Principal Scientist at Idenix (an MSD company), collaborating closely with Merck Boston and Westpoint. Trained as an organic synthetic chemist, he earned his PhD with Dr. R. Gree at the Ecole Nationale Supérieure de Chimie de Rennes and began his career at Molecumetics. He is co-author of more than 40 research publications and patents in antiviral, oncology, and CNS fields.

Dr. Mikhail Kalinichev is a seasoned pharmaceutical leader with over 20 years of broad, cross-functional experience spanning research and development, product innovation, and strategic partnerships, with a strong focus on CNS disorders. Before joining Neurosterix, he served as Head of Translational Science and a member of the Executive Leadership Team at Addex Therapeutics in Geneva, Switzerland. This marked his second tenure at Addex, where he had previously held roles including Associate Director and Group Leader of Behavioral Neuroscience. Prior to his return to Addex, Dr. Kalinichev spent six years as Director of In Vivo Neurology at Ipsen in France, where he played a key role in shaping the company’s neuroscience strategy, leading scientific teams, and establishing numerous industrial and academic collaborations in neuromuscular disorders and pain. Earlier in his career, he was Section Head at Lundbeck in Denmark, contributing to translational research in schizophrenia, cognitive impairment, and pain, and began his industry career as Principal Scientist at GlaxoSmithKline’s Psychiatry Center of Excellence in the UK.

Dr. Kalinichev completed postdoctoral training in pharmacology at Emory University School of Medicine and earned his PhD in behavioral and molecular neuroscience from Rutgers University. He is the recipient of multiple prestigious honors, including the Vernalis Prize from the British Association for Psychopharmacology and the GlaxoSmithKline Exceptional Science Award. He is an inventor on several patents and has co-authored more than 60 scientific papers and book chapters.

Dr. Jean-Philippe Rocher is Head of Pharmaceutical Development at Neurosterix. He has several decades of experience in medicinal chemistry and drug development. He played a pivotal role in the discovery and progression of multiple small molecules allosteric modulators programs, including the recent Neurosterix portfolio GPCRs programs and dipraglurant (mGlu5 NAM), ADX71149 (mGlu2 PAM), both of which moved to Phase 2 clinical development.

Dr. Rocher established the Company’s small molecule allosteric modulator chemistry platform when Joining Addex at its inception in 2002. Prior to joining Addex, Dr. Rocher has occupied the positions of Director of CNS Programs at Pierre Fabre (from March 2014 to May 2018). Senior Research Scientist for GlaxoSmithKline KK (Tsukuba, Japan), Scientific Project Leader in CNS at Mitsubishi Tanabe (Yokohama, Japan). He started his career as a Research Scientist in the Dermatology Research Center of Galderma (Sophia Antipolis, France) following a PhD in Medicinal Chemistry and Pharm D at the Faculty of Pharmacy of Lyon (France). He is a co author of more than 50 research publications and patents.

Holly Purcell, MBA, CPA is the Head of Finance at Neurosterix, with extensive experience providing financial and operational leadership across public and private biotechnology and medical technology companies from early-stage discovery through commercialization. Prior to joining Neurosterix, she was a Consulting CFO with Stout, Risius & Ross LLC and LS Associates, where she supported eight early-stage biotech companies in raising capital, securing non-dilutive funding, forecasting, and building finance and operations teams. She also served as Head of Finance at Xontogeny, LLC, overseeing the financial operations of the firm’s portfolio companies and supporting diligence for the Perceptive Xontogeny Venture Fund, a joint venture with Perceptive Advisors.

Earlier in her career, Ms. Purcell was VP of Finance and Corporate Secretary at Beta Bionics, Inc. (NASDAQ: BBNX) and played a key role in Vapotherm’s (NYSE: VAPO) initial public offering in 2018. She also held senior finance roles at several high-growth public and private medtech companies, where she was responsible for corporate accounting, internal and external financial reporting, financial planning and analysis, and Sarbanes-Oxley compliance. Ms. Purcell holds an MBA with a concentration in Corporate Social Responsibility from Southern New Hampshire University, a BA in Accounting from Assumption University, and is a licensed Certified Public Accountant (CPA) in the State of New Hampshire.

Lisa has over 20 years of experience in the pharmaceutical industry, most recently serving as the Vice President of Clinical Operations and Asset Lead at SFJ Pharmaceuticals where she was responsible for the management and execution of all clinical trials globally as well as leading their primary asset through its registrational Phase 3 program. Prior to joining SFJ, she served as the Senior Director of Clinical Development Operations at Alkermes, Inc. where she led global trial execution in oncology and CNS disorders including schizophrenia (oral and LAI), and multiple sclerosis contributing to multiple NDAs, sNDAs and BLAs.

Lisa’s industry experience includes leading Phase 1-3 and post-approval clinical development programs with oversight of clinical operations, data management, clinical programming, study start-up and patient recruitment and retention. She earned a bachelor’s degree in Exercise Science and Health Promotion from University of Maine-Orono and Master of Science from Florida Atlantic University in Boca Raton, Florida.

Fred Callori is CEO and a Co-Founder of Neurosterix. He is also a Managing Director at Perceptive Advisors, where he helps lead the firm’s venture strategy.

As Co-Founder and CEO of Neurosterix, Mr. Callori has been instrumental in shaping the company’s strategy, operations, and external relationships, building on his extensive experience in company creation, venture investment, and operational leadership at Perceptive.

Prior to joining Perceptive and co-founding Neurosterix, Mr. Callori was a Partner in the Life Science and Emerging Companies practices at Choate, Hall & Stewart LLP, where he advised investors and entrepreneurs on private equity and venture capital transactions.

He holds a BA in Economics from Binghamton University and a JD from Boston University School of Law.

Tim Dyer is a seasoned life sciences executive with more than two decades of leadership experience spanning finance, corporate development, and company building. He is the Co-Founder, CEO, Chief Financial Officer, and a member of the Board of Directors of Addex Therapeutics Ltd (SIX & Nasdaq: ADXN).

Since co-founding Addex in 2002, Mr. Dyer has been instrumental in driving the company’s strategic growth and execution. Under his leadership, Addex successfully completed its IPO and Nasdaq listing, established key industry partnerships, and advanced a robust pipeline of allosteric modulators targeting neurological disorders.

Mr. Dyer also led the spin-out of Neurosterix from Addex, serving as its CEO/CFO until May 2025. Earlier in his career, he spent ten years with PricewaterhouseCoopers in the United Kingdom and Switzerland as part of the audit and business advisory group, advising multinational clients in the life sciences sector.

In addition to his executive responsibilities, Mr. Dyer serves as Chairman of Stalicla SA, a clinical-stage precision medicine company focused on neurodevelopmental disorders, and as a Board Director of Multiwave Technologies AG, an innovator in medical imaging.

Mr. Dyer is a UK Chartered Accountant and holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Southampton.

Dr. Paskus is a Co-Founder of Neurosterix and currently a VP in Biotechnology at Perceptive Advisors. He joined Perceptive in 2021 as an Associate and focuses on public and private biotechnology companies. Previously, he was an analyst at a healthcare dedicated long/short equity hedge fund. He spent six years as an intramural fellow at the National Institutes of Health. He earned a Ph.D. in Neuroscience from the National Institutes of Health and Georgetown University Medical Center, and a B.A. in Neuroscience from Franklin & Marshall College.

Dr. Lawton, CBE is an accomplished pharmaceutical leader with more than 25 years of international experience at Merck & Co., Inc. He served as Vice President of MSD Europe and Managing Director of MSD UK until 2006, when he retired after a distinguished career spanning commercial, research, and senior management roles across France, the U.S., Canada, Spain, and throughout Europe. Under his leadership, MSD UK achieved sustained commercial success, becoming the fastest-growing company in the market for several years and launching numerous innovative medicines across therapeutic areas. In recognition of his contributions, he was appointed Commander of the Order of the British Empire (CBE) by Queen Elizabeth II in 2006. Dr. Lawton has also played an influential role in shaping UK healthcare policy. As President of the Association of the British Pharmaceutical Industry (ABPI), he negotiated industry pricing frameworks and worked with government to strengthen the UK’s position as a global leader in clinical research. He later served on the board of the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and was a founding member of several national initiatives, including the UK Clinical Research Collaboration and the Pharmaceutical Industry Competitiveness Task Force. In addition to his regulatory and industry leadership, Professor Lawton has served as Senior Strategy Adviser to Imperial College London’s Department of Medicine, consultant to leading healthcare organizations, and Chair of the Board of Addex Therapeutics. He holds undergraduate and doctoral degrees in Psychology from the University of London and is an Honorary Professor of the University of Wales.

Dr. Mirsaeedi-Farahani is a Co-Founder of Neurosterix and currently the Head of Therapeutics at Perceptive Advisors. He joined Perceptive in 2016 after earning an MD from the University of Pennsylvania and an MBA from the Harvard Business School. He previously spent two years as an analyst with McKinsey. Keyvan graduated Phi Beta Kappa from the University of Michigan with a BS in molecular biology as well as an undergraduate business degree.

Dr. Schoepp has more than 30 years of experience in the discovery and development of innovative neuroscience therapeutics within the pharmaceutical industry. He spent 20 years at Eli Lilly as a scientist and leader of the Neuroscience Research Department, followed by 11 years at Merck, where he served as Therapeutic Area Leader for Neuroscience Research. Over the course of his career, Dr. Schoepp has authored more than 200 peer-reviewed publications and is an inventor on 15 U.S. patents. His pioneering research has made significant contributions to understanding the role of the excitatory amino acid neurotransmitter glutamate in disease pathophysiology, pharmacology, and therapeutics. He played a central role in the discovery of the first AMPA/kainate and metabotropic receptor modulators—both negative and positive—for conditions including migraine, pain, cognitive impairment, anxiety disorders, and schizophrenia. While at Lilly, Dr. Schoepp co-discovered alvimopan (Entereg), the first-in-class peripherally restricted opioid antagonist approved for post-operative ileus. At Merck, he and his team built a robust pipeline of first-in-class agents targeting Alzheimer’s disease, Parkinson’s disease, pain/migraine, and schizophrenia. Notably, this work led to the development of suvorexant (Belsomra), the first orexin receptor antagonist approved for insomnia, and ubrogepant (Ubrelvy), the first oral CGRP antagonist approved for migraine treatment. Dr. Schoepp earned his PhD in toxicology and pharmacology from West Virginia University.

Dr. Hill is an internationally recognized pharmacologist with more than four decades of experience in academia, pharmaceutical R&D, and advisory leadership. He is currently Visiting Professor of Pharmacology at Imperial College London and Non-Executive Director of Avilex (Denmark) and Addex (Switzerland). Dr. Hill spent nearly 20 years at Merck, where he served as Executive Director of Pharmacology at the Merck Neuroscience Research Centre with additional oversight of neuroscience research at Banyu Research Labs in Tsukuba, Japan. He later became Executive Director of Licensing and External Research for Europe before retiring from the company. During his tenure at Merck, he chaired multiple discovery project teams, including those that led to the marketed therapies Maxalt® for migraine and Emend® for chemotherapy-induced nausea and vomiting. Earlier in his career, he was Head of Biology and a founding member of the Parke-Davis Cambridge Research Unit, Group Director of Pharmacology at SK&F, a Lecturer in Pharmacology at the University of Bristol, and a Supervisor in Pharmacology at Downing College, University of Cambridge. Dr. Hill has held numerous scientific and advisory leadership positions, including Chair of the SAB at Asceneuron, Non-Executive Director of Orexo AB, and Council Member of the UK Academy of Medical Sciences. He also served on the UK Government’s Advisory Council on the Misuse of Drugs and continues to contribute to its working groups on medicinal cannabis and drug misuse. He received his BPharm and PhD in Pharmacology from the University of London, was awarded an Honorary DSc from the University of Bradford in 2004, and was elected a Fellow of the Academy of Medical Sciences in 2005. Dr. Hill is also President Emeritus of the British Pharmacological Society.

Dr. Saccomano is the President, Chief Executive Officer and a member of the Board of OnKure Therapeutics. He is a biopharmaceutical professional with nearly 35 years of experience leading pharmaceutical research and development across multiple therapeutic areas. Prior to OnKure, he was the Chief Science Officer and Site Head at Pfizer’s Boulder facility, leading a team of 170 research scientists focused on small molecule drug programs. Dr. Saccomano oversaw the discovery and progression of multiple central nervous system drugs, including ziprasidone, marketed by Pfizer as Geodon®; donepezil, marketed by Eisai and Pfizer as Aricept®; and varenicline, marketed by Pfizer as Chantix®. Prior to working at Pfizer, Dr. Saccomano served as Chief Science Officer at Array BioPharma Inc., where he was responsible for creating and advancing ten clinical-stage compounds, with seven drug approvals. Dr. Saccomano also served as Chief Technology Officer at SomaLogic Inc., where he managed scientific and technical teams in charge of advancing elements of the company’s proteomic platform. He currently serves as a scientific advisor and on the board of directors of several innovative companies, including Neurosterix. Dr. Saccomano received a B.S. from the State University of New York at Buffalo and a Ph.D. in Organic Chemistry from Columbia University under the direction of Gilbert Stork.

Dr. Bernstein is a medicinal chemist with more than 30 years of experience in CNS drug discovery and development. After earning his PhD at Columbia University under Professor Gilbert Stork and completing postdoctoral training with Professor Barry Trost at the University of Wisconsin–Madison, he began his career in 1979 at ICI Pharmaceuticals in Wilmington, DE. He went on to spend 31 years with the company through its transitions to Zeneca and AstraZeneca, ultimately serving as Senior Principal Scientist of CNS Chemistry. Throughout his career, Dr. Bernstein has contributed to programs spanning multiple therapeutic areas and mechanisms of action, with more than ten compounds advancing into clinical development. He is the author of over 200 publications, presentations, and patents, and has been widely recognized for his contributions to medicinal chemistry. Since retiring from AstraZeneca in 2010, Dr. Bernstein has led PhaRmaB LLC, a consulting platform through which he provides strategic guidance and mentorship in drug discovery and development. He remains active in the field as an Adjunct Professor of Chemistry & Biochemistry at the University of Delaware, as an editor for leading medicine chemistry journals, and as a board member and strategic advisor for several companies in the scientific community, including Nxera (formerly Sosei Heptares) and Richter Gedeon Nyrt.

Christoph U. Correll, MD, is Clinical Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, USA, and also Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany again.

Dr. Correll focuses on the identification and treatment of youth and adults with severe mental illness, clinical trials, epidemiology, psychopharmacology, meta-research, and physical health in mental health. He has authored over 1,000 articles that have been cited more than 100,000 times and received over 40 research awards. Since 2014, the beginning of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry” (https://hcr.clarivate.com). Additionally, Dr. Correll has been holding numerous Expertscape rankings based on the number of publications and citations in the past 10 years, including being ranked consistently since 2017 as the number one most cited world expert in >10 areas, including “central nervous system agents”, “psychotropic drugs“, “schizophrenia”, “schizophrenia spectrum and other psychotic disorders”, “antipsychotics”, “delayed action preparations”, “olanzapine” and “weight gain”.